Publication Name	World Journal of Clinical Oncology
Manuscript ID	64862
Country	Finland

Received	2021-02-25 13:35
Peer-Review Started	2021-02-25 13:38
To Make the First Decision
Return for Revision	2021-05-07 20:27
Revised	2021-05-12 12:07
Second Decision	2021-08-06 03:17
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2021-08-06 06:56
Articles in Press	2021-08-06 06:56
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2021-08-19 15:19
Publish the Manuscript Online	2021-08-23 06:43

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Minireviews
Article Title	Current challenges in applying gene-driven therapies in clinical lung cancer practice
Manuscript Source	Invited Manuscript
All Author List	Jatta Saarenheimo, Heidi Andersen, Natalja Eigeliene and Antti P Jekunen
ORCID	Author(s) ORCID Number Jatta Saarenheimo http://orcid.org/0000-0002-2580-2830 Heidi Andersen http://orcid.org/0000-0001-5923-5865 Natalja Eigeliene http://orcid.org/0000-0003-0076-9322 Antti P Jekunen http://orcid.org/0000-0002-6183-0169
Funding Agency and Grant Number
Corresponding Author	Jatta Saarenheimo, PhD, Research Scientist, Department of Pathology, Vasa Central Hospital, Hietalahdenkatu 2-4, Vaasa 65130, Finland. jatta.saarenheimo@vshp.fi
Key Words	Cancer drug; Availability; Gene testing; Tissue sampling; Lung cancer
Core Tip	Several gene-driven therapy drugs and molecular testing, together with immunohistochemistry, have evolved for lung cancer in recent years. Lung cancer is mutation dense and has more predictive genes that potentially influence treatment decisions than any other cancer type. In our case study, we ran into obstacles and delays in the diagnostic pathway both in tissue sampling and in gene testing. However, the major obstacle was the financial availability of new drugs. All elements need to be in place before a new drug can be given to patients, following the idea of the right drug at the right time.
Publish Date	2021-08-23 06:43
Citation	Saarenheimo J, Andersen H, Eigeliene N, Jekunen AP. Current challenges in applying gene-driven therapies in clinical lung cancer practice. World J Clin Oncol 2021; 12(8): 656-663
URL	https://www.wjgnet.com/2218-4333/full/v12/i8/656.htm
DOI	https://dx.doi.org/10.5306/wjco.v12.i8.656

Full Article (PDF)	WJCO-12-656.pdf
Full Article (Word)	WJCO-12-656.docx
Manuscript File	64862_Auto_Edited-JPY.docx
Answering Reviewers	64862-Answering reviewers.pdf
Audio Core Tip	64862-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	64862-Conflict-of-interest statement.pdf
Copyright License Agreement	64862-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	64862-Language certificate.pdf
Peer-review Report	64862-Peer-review(s).pdf
Scientific Misconduct Check	64862-Bing-Wang JL-1.jpg
Scientific Misconduct Check	64862-Bing-Wu YXJ-2.jpg
Scientific Misconduct Check	64862-Scientific misconduct check.pdf
Scientific Editor Work List	64862-Scientific editor work list.pdf